Regulation - Cubicin, Antibiotics and Infectious diseases

Filter

Popular Filters

FDA accepts priority review of Durata NDA for Dalvance

FDA accepts priority review of Durata NDA for Dalvance

27-11-2013

Shares of Durata Therapeutics leapt 13.4%, following the news that the New Drug Application for its investigational…

Antibiotics and Infectious diseasesCubicinDalvanceDurata TherapeuticsNorth AmericaPharmaceuticalRegulation

Back to top